TAKEDA Terminates Phase 3 Soticlestat Study in Dravet and Lennox-Gastaut

Takeda has halted a Phase 3 trial of soticlestat in epilepsy patients previously exposed to fenfluramine, citing a business decision unrelated to patient safety.

Share
Takeda has stopped a late-stage study of its epilepsy candidate soticlestat.